Editas Medicine Stock Price, News & Analysis (NASDAQ:EDIT) $10.99 -0.12 (-1.08%) (As of 02:39 PM ET) Add Compare Share Share Today's Range$10.77▼$11.2050-Day Range$6.25▼$11.1152-Week Range$6.08▼$11.93Volume1.08 million shsAverage Volume1.81 million shsMarket Capitalization$897.55 millionP/E RatioN/ADividend YieldN/APrice Target$13.92 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Editas Medicine MarketRank™ Stock AnalysisAnalyst RatingHold2.33 Rating ScoreUpside/Downside27.2% Upside$13.92 Price TargetShort InterestHealthy19.43% of Shares Sold ShortDividend StrengthN/ASustainability-0.63Upright™ Environmental ScoreNews SentimentN/AInsider TradingSelling Shares$1,168 Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($2.40) to ($2.55) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.20 out of 5 starsMedical Sector617th out of 958 stocksBiotechnology Industry43rd out of 78 stocks 3.2 Analyst's Opinion Consensus RatingEditas Medicine has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 5 buy ratings, 6 hold ratings, and 1 sell rating.Price Target Upside/DownsideAccording to analysts' consensus price target of $13.92, Editas Medicine has a forecasted upside of 27.2% from its current price of $10.94.Amount of Analyst CoverageEditas Medicine has only been the subject of 4 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted19.43% of the outstanding shares of Editas Medicine have been sold short.Short Interest Ratio / Days to CoverEditas Medicine has a short interest ratio ("days to cover") of 9.7.Change versus previous monthShort interest in Editas Medicine has recently decreased by 5.37%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldEditas Medicine does not currently pay a dividend.Dividend GrowthEditas Medicine does not have a long track record of dividend growth. Previous Next 4.6 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreEditas Medicine has received a 71.49% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Preclinical research services for physical health", "Clinical research services for physical health", and "Clinical research services for genetic diseases" products. See details.Environmental SustainabilityThe Environmental Impact score for Editas Medicine is -0.63. Previous Next 2.4 News and Social Media Coverage News SentimentEditas Medicine has a news sentiment score of 0.33. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.50 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Editas Medicine this week, compared to 3 articles on an average week.Search Interest14 people have searched for EDIT on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat Follows15 people have added Editas Medicine to their MarketBeat watchlist in the last 30 days. This is an increase of 114% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Editas Medicine insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,168.00 in company stock.Percentage Held by InsidersOnly 2.20% of the stock of Editas Medicine is held by insiders.Percentage Held by Institutions76.61% of the stock of Editas Medicine is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Editas Medicine are expected to decrease in the coming year, from ($2.40) to ($2.55) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Editas Medicine is -4.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Editas Medicine is -4.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioEditas Medicine has a P/B Ratio of 2.08. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Editas Medicine Stock (NASDAQ:EDIT)Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis 10; autosomal dominant retinitis pigmentosa; and EDIT-301, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing gene-edited Natural Killer cell medicines to treat solid tumor cancers; alpha-beta T cells for multiple cancers; and gamma delta T cell therapies to treat cancer. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited to discover, develop, and commercialize new gene editing medicines for a range of ocular disorders. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.Read More EDIT Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart EDIT Stock News HeadlinesDecember 5, 2023 | americanbankingnews.comShort Interest in Editas Medicine, Inc. (NASDAQ:EDIT) Decreases By 5.4%November 29, 2023 | morningstar.comEditas Medicine Inc EDITDecember 7, 2023 | Edge On The Street (Ad)The Battery Metal Nobody Told You AboutAccording to McKinsey and Company, the battery storage market is growing rapidly, especially with the transition to clean, renewable energy. Lithium-ion batteries still grab most of the headlines. But analysts now call safe and long-lasting batteries made with vanadium "the future of battery tech." November 28, 2023 | seekingalpha.comEditas Medicine, Inc. (EDIT) 6th Annual Evercore ISI HealthCONx Conference (Transcript)November 27, 2023 | finance.yahoo.comEditas Medicine, Inc. (NASDAQ:EDIT) is a favorite amongst institutional investors who own 69%November 25, 2023 | seekingalpha.comCRISPR-Cas9 Gene Editing Is On The Cusp Of Something BigNovember 14, 2023 | seekingalpha.comEditas Medicine, Inc. (EDIT) Presents at Stifel 2023 Healthcare Conference (Transcript)November 8, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: IN8bio (INAB) and Editas Medicine (EDIT)December 7, 2023 | Edge On The Street (Ad)The Battery Metal Nobody Told You AboutAccording to McKinsey and Company, the battery storage market is growing rapidly, especially with the transition to clean, renewable energy. Lithium-ion batteries still grab most of the headlines. But analysts now call safe and long-lasting batteries made with vanadium "the future of battery tech." November 8, 2023 | markets.businessinsider.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Editas Medicine (EDIT), Corvus Pharmaceuticals (CRVS) and AC Immune SA (ACIU)November 6, 2023 | markets.businessinsider.comRBC Capital Keeps Their Hold Rating on Editas Medicine (EDIT)November 6, 2023 | finance.yahoo.comEditas (EDIT) Q3 Earnings & Revenues Beat, Pipeline in FocusNovember 5, 2023 | finance.yahoo.comEditas Medicine, Inc. (NASDAQ:EDIT) Q3 2023 Earnings Call TranscriptNovember 5, 2023 | hk.finance.yahoo.comEditas Medicine Inc (EDIT) Q3 2023 Earnings: Net Loss Narrows to $45.November 3, 2023 | msn.comEditas Medicine spikes after Q3 resultsNovember 3, 2023 | marketwatch.comEditas Medicine Shares Climb 20% on 3Q Revenue Growth, Narrower LossNovember 3, 2023 | msn.comEditas Medicine beats top and bottom line estimatesNovember 3, 2023 | finance.yahoo.comEditas Medicine Announces Third Quarter 2023 Results and Business UpdatesNovember 3, 2023 | finance.yahoo.comEditas Medicine Inc (EDIT) Q3 2023 Earnings: Net Loss Narrows to $45. ...November 2, 2023 | markets.businessinsider.comEditas Medicine is about to announce earnings — here's what Wall Street expectsNovember 2, 2023 | msn.comEditas Medicine Q3 2023 Earnings PreviewNovember 2, 2023 | finance.yahoo.comEditas Medicine to Present Clinical Data from the RUBY and EdiTHAL Trials of EDIT-301 at the ASH 2023 Annual Meeting and in a Company-sponsored WebinarOctober 29, 2023 | za.investing.comPinterest Primed for Rich Ad Spend; Adobe a Powerhouse: Street Calls of the WeekOctober 25, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Intuitive Surgical (ISRG), Editas Medicine (EDIT) and Revolution Medicines (RVMD)October 24, 2023 | msn.comCitigroup Upgrades Editas Medicine (EDIT)October 18, 2023 | msn.comJP Morgan Upgrades Editas Medicine (EDIT)October 17, 2023 | msn.comCantor Fitzgerald Downgrades Editas Medicine (EDIT)See More Headlines Receive EDIT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Editas Medicine and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/03/2023Today12/07/2023Fiscal Year End12/31/2023Next Earnings (Estimated)2/28/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biotechnology Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:EDIT CUSIPN/A CIK1650664 Webwww.editasmedicine.com Phone(617) 401-9000FaxN/AEmployees226Year FoundedN/APrice Target and Rating Average Stock Price Target$13.92 High Stock Price Target$30.00 Low Stock Price Target$7.00 Potential Upside/Downside+25.9%Consensus RatingHold Rating Score (0-4)2.33 Research Coverage12 Analysts Profitability EPS (Most Recent Fiscal Year)($2.70) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-220,430,000.00 Net Margins-792.70% Pretax Margin-792.70% Return on Equity-54.24% Return on Assets-38.53% Debt Debt-to-Equity RatioN/A Current Ratio6.12 Quick Ratio6.12 Sales & Book Value Annual Sales$19.71 million Price / Sales45.79 Cash FlowN/A Price / Cash FlowN/A Book Value$5.25 per share Price / Book2.10Miscellaneous Outstanding Shares81,670,000Free Float79,877,000Market Cap$902.45 million OptionableOptionable Beta1.96 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report Key ExecutivesDr. Gilmore O'Neill (Age 59)President, CEO & Director Comp: $815.37kDr. Bruce E. Eaton Ph.D. (Age 69)Executive VP, CTO & Chief Business Officer Comp: $786.23kDr. Baisong Mei M.D.Ph.D., Senior VP & Chief Medical OfficerDr. Feng Zhang Ph.D.Co-Founder & Scientific Advisory Board MemberDr. George McDonald Church Ph.D. (Age 69)Co-Founder & Scientific Advisory Board Member Dr. J. Keith Joung M.D.Ph.D., Co-Founder & Scientific Advisory Board MemberDr. David R. Liu Ph.D.Co-Founder & Scientific Advisory Board MemberMr. Erick J. Lucera C.F.A. (Age 55)CPA, CFO & Executive VP Mr. Harry R. Gill III (Age 62)Senior Vice President of Operations Dr. Linda C. Burkly Ph.D.Executive VP & Chief Scientific OfficerMore ExecutivesKey CompetitorsKura OncologyNASDAQ:KURAIntercept PharmaceuticalsNASDAQ:ICPTSana BiotechnologyNASDAQ:SANARelay TherapeuticsNASDAQ:RLAYGeronNASDAQ:GERNView All CompetitorsInsiders & InstitutionsCitigroup Inc.Bought 25,532 shares on 12/6/2023Ownership: 0.260%American Century Companies Inc.Bought 19,451 shares on 11/30/2023Ownership: 0.066%Deutsche Bank AGBought 4,651 shares on 11/24/2023Ownership: 0.088%Comerica BankBought 15,902 shares on 11/21/2023Ownership: 0.019%Walleye Trading LLCSold 5,800 shares on 11/21/2023Ownership: 0.000%View All Insider TransactionsView All Institutional Transactions EDIT Stock Analysis - Frequently Asked Questions Should I buy or sell Editas Medicine stock right now? 12 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Editas Medicine in the last twelve months. There are currently 1 sell rating, 6 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" EDIT shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in EDIT, but not buy additional shares or sell existing shares. View EDIT analyst ratings or view top-rated stocks. What is Editas Medicine's stock price target for 2024? 12 analysts have issued 1 year target prices for Editas Medicine's stock. Their EDIT share price targets range from $7.00 to $30.00. On average, they anticipate the company's stock price to reach $13.92 in the next twelve months. This suggests a possible upside of 27.2% from the stock's current price. View analysts price targets for EDIT or view top-rated stocks among Wall Street analysts. How have EDIT shares performed in 2023? Editas Medicine's stock was trading at $8.87 on January 1st, 2023. Since then, EDIT shares have increased by 23.3% and is now trading at $10.94. View the best growth stocks for 2023 here. Are investors shorting Editas Medicine? Editas Medicine saw a drop in short interest in November. As of November 15th, there was short interest totaling 15,870,000 shares, a drop of 5.4% from the October 31st total of 16,770,000 shares. Based on an average daily volume of 1,630,000 shares, the short-interest ratio is currently 9.7 days. View Editas Medicine's Short Interest. When is Editas Medicine's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, February 28th 2024. View our EDIT earnings forecast. How were Editas Medicine's earnings last quarter? Editas Medicine, Inc. (NASDAQ:EDIT) posted its earnings results on Friday, November, 3rd. The company reported ($0.55) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.64) by $0.09. The company earned $5.34 million during the quarter, compared to the consensus estimate of $3.70 million. Editas Medicine had a negative trailing twelve-month return on equity of 54.24% and a negative net margin of 792.70%. The company's revenue was up 1171.4% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.81) earnings per share. What ETFs hold Editas Medicine's stock? ETFs with the largest weight of Editas Medicine (NASDAQ:EDIT) stock in their portfolio include Kelly CRISPR & Gene Editing Technology ETF (XDNA), iShares Genomics Immunology and Healthcare ETF (IDNA), Horizon Kinetics Medical ETF (MEDX), Direxion Moonshot Innovators ETF (MOON), Global X Genomics & Biotechnology ETF (GNOM) and AXS Green Alpha ETF (NXTE).WisdomTree BioRevolution Fund (WDNA) and What other stocks do shareholders of Editas Medicine own? Based on aggregate information from My MarketBeat watchlists, some companies that other Editas Medicine investors own include CRISPR Therapeutics (CRSP), NVIDIA (NVDA), Micron Technology (MU), Intellia Therapeutics (NTLA), Block (SQ), Advanced Micro Devices (AMD), Alibaba Group (BABA), QUALCOMM (QCOM), Cisco Systems (CSCO) and Skyworks Solutions (SWKS). When did Editas Medicine IPO? (EDIT) raised $100 million in an initial public offering (IPO) on Wednesday, February 3rd 2016. The company issued 5,900,000 shares at a price of $16.00-$18.00 per share. Morgan Stanley and J.P. Morgan acted as the underwriters for the IPO and Cowen and Company and JMP Securities were co-managers. Who are Editas Medicine's major shareholders? Editas Medicine's stock is owned by a variety of retail and institutional investors. Top institutional investors include Northern Trust Corp (1.09%), Charles Schwab Investment Management Inc. (0.84%), Rafferty Asset Management LLC (0.69%), Mirae Asset Global Investments Co. Ltd. (0.46%), Bank of New York Mellon Corp (0.38%) and Barclays PLC (0.34%). Insiders that own company stock include Baisong Mei, Bruce Eaton, Charles Albright, Gilmore Neil O'neill, James C Mullen, Lisa Anne Michaels, Mark S Shearman and Michelle Robertson. View institutional ownership trends. How do I buy shares of Editas Medicine? Shares of EDIT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (NASDAQ:EDIT) was last updated on 12/7/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Editas Medicine, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.